Entering text into the input field will update the search result below

Cassava Sciences nabs new U.S. patent covering lead drug

  • Cassava Sciences (SAVA) secures a new U.S. patent covering lead candidate sumifilam (PTI-125). The claims pertain to inhibiting a TLR4-mediated immune response via one or more unique filamin A-binding molecules.
  • Its patent estate, now totaling seven, in the area of filamin-binding molecules runs through 2037.
  • The company says sumifilam restores the normal shape of filamin A in the brain, improving the function of multiple brain receptors and dampening neuroinflammation in Alzheimer’s patients.
  • Previously: Cassava Sciences rallies on hopes for Alzheimer's candiate PTI-125 (June 3)

Recommended For You

About SAVA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SAVA--
Cassava Sciences, Inc.